Shopping Cart

Your shopping cart is currently empty

GSK2324

Name: GSK2324
Brand: TargetMol
SKU: T27460
Price: 342 USD
Availability: InStock
Rating: 5 (10 reviews)

Copy Product Info

😃Good

Catalog No. T27460Cas No. 1020567-30-9

Alias GSK-2324, GSK 2324

GSK2324 is a potent FXR agonist for the treatment of NAFLD by controlling hepatic lipids through reduced uptake and selective reduction of fatty acid synthesis.

GSK2324

Copy Product Info

😃Good

Purity: 99.02%

Catalog No. T27460Alias GSK-2324, GSK 2324Cas No. 1020567-30-9

GSK2324 is a potent FXR agonist for the treatment of NAFLD by controlling hepatic lipids through reduced uptake and selective reduction of fatty acid synthesis.

Pack Size	Price	USA Warehouse	Global Warehouse
1 mg	$342	In Stock	In Stock
5 mg	$828	In Stock	In Stock
10 mg	$1,130	-	In Stock
25 mg	$1,680	-	In Stock
50 mg	$2,290	-	In Stock
100 mg	$2,970	-	In Stock

Add to Cart

Add to Quotation

In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]

This molecule is a custom-made product. TargetMol has an excellent synthesis team with the experience and capability to provide you with cost-effective products.If you have any questions, please feel free to contact us. We are committed to serving you wholeheartedly.

All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.

Questions

Batch Information

Select Batch

Purity:99.02%

Appearance:Solid

Color:White to Yellow

Resource Download

COA HNMR LCMS

Product Introduction

GSK2324 AI Summary

GSK2324 exhibits agonist activity at human FXR LBD, demonstrated through FRET assay and transactivation of luciferase reporter gene expression, with EC50 values of 120.0 nM and 50.0 nM, respectively. It shows maximum efficacy of 102.0% compared to the standard compound GW4064 in the CV1 cell-based assay. GSK2324 effectively reduces body weight, and various serum levels—including glucose, insulin, total cholesterol, triglycerides, NEFA, glycerol, and beta-hydroxybutyrate—in diet-induced obese mice over a 4-week period. It has selectivity for human FXR over other receptors and exhibits inhibitory effects on specific human liver microsomal enzymes. In pharmacokinetic studies, it demonstrates a terminal half-life of 2.833 hours, a clearance rate of 32.0 mL.min-1.kg-1, and a volume of distribution at steady state of 3.4 L.kg-1 in rats. Additionally, its oral bioavailability is 23.0% at a 5 mg/kg dose in rats, with a dose-normalized AUC of 130.0 ng.hr.kg/ml.mg. However, it has limited oral bioavailability with variations across different animal models..

Note: Summary generated by AI. Data source: ChEMBL

Bioactivity

Description	GSK2324 is a potent FXR agonist for the treatment of NAFLD by controlling hepatic lipids through reduced uptake and selective reduction of fatty acid synthesis.
Synonyms	GSK-2324, GSK 2324

Chemical Properties

Molecular Weight	533.4
Formula	C₂₉H₂₂Cl₂N₂O₄
Cas No.	1020567-30-9
Smiles	C(OC1=CC=C(C=C1)C2=CC3=C(C=C2)N=C(C(O)=O)C=C3)C=4C(=NOC4C(C)C)C5=C(Cl)C=CC=C5Cl
Relative Density.	1.351 g/cm3 (Predicted)

Storage & Solubility Information

Storage

keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.

Solubility Information

DMSO: 100 mg/mL (187.48 mM), Sonication is recommended.

H2O: < 1 mg/mL (insoluble or slightly soluble)

Solution Preparation Table

DMSO

	1mg	5mg	10mg	50mg
1 mM	1.8748 mL	9.3738 mL	18.7477 mL	93.7383 mL
5 mM	0.3750 mL	1.8748 mL	3.7495 mL	18.7477 mL
10 mM	0.1875 mL	0.9374 mL	1.8748 mL	9.3738 mL
20 mM	0.0937 mL	0.4687 mL	0.9374 mL	4.6869 mL
50 mM	0.0375 mL	0.1875 mL	0.3750 mL	1.8748 mL
100 mM	0.0187 mL	0.0937 mL	0.1875 mL	0.9374 mL

Calculator

Molarity Calculator
Dilution Calculator
Reconstitution Calculator
Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:

For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, TargetMol | Animal experiments

and a total of 10 animals are to be administered, using a formulation of TargetMol | reagent

10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH₂O , the resulting working solution concentration would be 2 mg/mL.

Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSO TargetMol | reagent to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSO TargetMol | reagent stock solution to 400 μL PEG300 and mix thoroughly until the solution becomes clear.

2) Add 50 μL Tween 80 and mix well until fully clarified.

3) Add 450 μL Saline,PBS or ddH₂O TargetMol | reagent and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.

All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc